Alexander Belcredi is a seasoned biotech entrepreneur, who has been working in the pharmaceutical industry for over a decade. In 2017, he co-founded PhagoMed Biopharma GmbH, a biotech company developing phage-based pharmaceuticals to treat bacterial infections. At PhagoMed he served as a Co-CEO and focused on the Business & Finance responsibilities. PhagoMed was successfully exited to BioNTech in late 2021 and Alexander now co-leads the BioNTech research hub in Austria. Prior to founding PhagoMed, Alexander worked at the Boston Consulting Group for nine years, where he advised pharmaceutical and MedTech clients on strategy and organizational development. Alexander holds an MA in Modern History and Economics from the University of St. Andrews as well as an MBA from INSEAD.